Dr. Paurush Babbar of The Urology Group talks with Lincoln Ware of The Buzz 1230AM about Low-T therapies, breaking down myths and misconceptions.
Dr. Gary Kirsh, president of The Urology Group, was a co-author in this article, recently published in Reviews in Urology.
“Since its initial charter as a trade organization representing the interests of urology practices of 10 physician members or more, LUGPA has expanded its mission to include smaller group practices that are equally committed to providing integrated, comprehensive services to patients suffering from genitourinary disease. LUGPA currently represents 145 urology group practices in the United States, with more than 2200 physicians who, in 2016, collectively provided approximately 35% of the nation’s urology services.1 From the outset, LUGPA’s mission has been to advance the independent practice of urology by advocating for independent physicians’ ability to access technology in their practices; to cultivate clinical, business, and administrative excellence; and to recruit and support future leaders in urology. LUGPA is an organization of practices, not a medical society—as such, it occupies a unique niche in the specialty of urology.”
The Urology Group seeks to help patients with advanced prostate cancer find drugs like Pluvicto that are in short supply. One patient received his medication from Italy due to limited quantities in the U.S. Being your own advocate is essential to making sure you can take advantage of every treatment option available.
A recent article in Romper Magazine revealed that although vasectomies are simpler, safer, and less expensive, tubal ligations (getting one’s “tubes tied”) outpace them 3 to 1 in the United States and are still performed far more often worldwide. In this article The Urology Group’s Dr. Paurush Babbar debunks common myths and fears men have about getting a…